大细胞衍生胰岛素抗剂ImpL2在细菌感染时诱导脂蛋白调动
Gabriela Krejčová1, Cecilia Morgantini2, Helena Zemanová1
1Department of Molecular Biology and Genetics, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic.
The EMBO journal
|October 9, 2023
概括
免疫细胞需要能量,所以它们向身体发出信号,要求释放营养. 这种涉及ImpL2/IGFBP7的保存机制,通过将能量重定向到免疫细胞,有助于对抗感染.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢调节 代谢调节 代谢调节
- 细胞生物学 细胞生物学
背景情况:
- 免疫反应耗费大量能量,需要全身代谢调整以提供营养.
- 协调免疫功能和宿主新陈代谢的精确机制尚未完全理解.
研究的目的:
- 阐明将免疫激活与系统代谢变化联系起来的分子机制.
- 确定调节免疫细胞营养可用性的保护途径.
主要方法:
- 研究了HIF1α在Drosophila巨细胞在促炎性两极化过程中的作用.
- 分析了胰岛素抗剂ImpL2的产生及其对胰岛素信号传递的影响.
- 研究了免疫激活巨细胞中的哺乳动物同类IGFBP7及其对脂蛋白调动的影响.
主要成果:
- 亲炎性多索菲拉巨细胞通过HIF1α对ImpL2进行上调,损害胰岛素信号传递和调动脂蛋白.
- 哺乳动物的巨细胞也在免疫激活时以依赖HIF1α的方式产生IGFBP7.
- 巨细胞衍生的ImpL2/IGFBP7通过减少中央代谢器官中的胰岛素信号来保护营养.
结论:
- 巨细胞生产ImpL2/IGFBP7是一种进化保存的机制,用于支持免疫功能.
- 这一途径通过调节全身胰岛素信号传递,确保免疫细胞在感染期间获得营养.
- 了解这种相互作用对于开发提高宿主对病原体耐药性的策略至关重要.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Glucagon-like Receptor Agonists
337
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
337


